Highland Capital Management (Texas)’s Alexion Pharmaceuticals ALXN Stock Holding History

Highland Capital Management (Texas)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,950	Closed	-$774K	–	384
2018 Q1	$774K	Buy	6,950 +1,300	+23%	+$155K	0.04%	197
2017 Q4	$675K	Sell	5,650 -16,300	-74%	-$1.99M	0.03%	188
2017 Q3	$3.08M	Sell	21,950 -1,900	-8%	-$258K	0.14%	127
2017 Q2	$2.9M	Hold	23,850	–	–	0.12%	125
2017 Q1	$2.89M	Sell	23,850 -34,450	-59%	-$4.44M	0.15%	126
2016 Q4	$7.13M	Buy	58,300 +34,450	+144%	+$4.22M	0.33%	75
2016 Q3	$2.92M	Sell	23,850 -34,075	-59%	-$4.39M	0.09%	157
2016 Q2	$6.76M	Sell	57,925 -52,364	-47%	-$7.43M	0.28%	98
2016 Q1	$15.4M	Buy	+110,289	New	+$16.2M	0.68%	39
2014 Q3	–	Sell	-19,768	Closed	-$3.09M	–	287
2014 Q2	$3.09M	Buy	+19,768	New	+$3.12M	0.11%	120

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highland Capital Management (Texas)'s ALXN Position: Q2 2018 in Review

Highland Capital Management (Texas) sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 6,950 shares — an estimated $774K sold.

Highland Capital Management (Texas) first reported a position in ALXN in Q2 2014 and held it in 10 quarters. The position peaked at $15.4M in Q1 2016. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Highland Capital Management (Texas) reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Highland Capital Management (Texas) sold 6,950 Alexion Pharmaceuticals shares in Q2 2018, an estimated $774K.
Highland Capital Management (Texas) first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Highland Capital Management (Texas)'s Alexion Pharmaceuticals position peaked at $15.4M in Q1 2016.
601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2018, filed 14 Aug 2018.